Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28510819 | 0.78 | RAB9A (0.46) | RAB9ANPC1ASIC3ADORA2AADORA1 | |
| SCHEMBL714891 | 0.76 | ASIC3 (0.38) | RAB9ANPC1ASIC3ADORA2AADORA1 | |
| SCHEMBL715045 | 0.72 | MEN1 (0.61) | RAB9ANPC1ASIC3ADORA2AADORA1 | |
| SCHEMBL715959 | 0.71 | RAB9A (0.65) | RAB9ANPC1MEN1KMT2A | |
| SCHEMBL714896 | 0.69 | HSD17B1 (0.46) | RAB9ANPC1MEN1KMT2A | |
| SCHEMBL715745 | 0.69 | RAB9A (0.44) | RAB9ANPC1CYP11B1CYP11B2MEN1 | |
| SCHEMBL28511914 | 0.69 | NPC1 (0.46) | RAB9ANPC1ADORA2AADORA1 | |
| SCHEMBL28906122 | 0.69 | NPC1 (0.51) | RAB9ANPC1ADORA2AADORA1MEN1 | |
| SCHEMBL714570 | 0.69 | ASIC3 (0.50) | RAB9ANPC1ASIC3ADORA2AADORA1 | |
| SCHEMBL28501588 | 0.69 | NPC1 (0.51) | RAB9ANPC1ADORA2AADORA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8771843-B2 | Fluorene derivative, organic compound, and light-emitting element, light-emitting device, and electronic device using the compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20120049768-A1 | Fluorene Derivative, Organic Compound, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120049768-A1 | Fluorene Derivative, Organic Compound, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Compound | AFF2, MAPRE2, AFF4 | RAB9A 440/4885NPC1 2154/4885ASIC3 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.